© Merck KGaAThe Merck subsidiary EMD Serono has agreed to price reductions of up to 84% for its in vitro fertilisation products in the United States. To avoid paying pharmaceutical tariffs, the company will distribute the products directly to self-paying patients via the TrumpRx.gov platform from 2026.
Watch this expert-led session to explore the latest trends and insights in gene therapy, including how to model immunosuppressive regimens, key study-design considerations, and the importance of age categories in nonhuman primate research.
Adcytherix SASFrench ADC start-up Adcytherix SAS has added €105m Series A funding to a €30m seed financing round closed last year. With the money, the company will start a Phase I study with its lead ADCX-020 in Q1 2026 and develop novel payloads to break ADC therapy resistance.
Tubulis GmbHMunich-Martinsried-based biotech Tubulis has closed a €308 million (USD 361 million) Series C financing round – the largest of its kind for a still existing European biotechnology company at the Series C stage and also the world’s largest financing for a private ADC (antibody–drug conjugate) developer. The attractivity lays in the technologyplatform of linking the payload.
BioMed NVMainz Biomed NV may have taken a major step in early pancreatic cancer detection. The company reports that its multivariate RNA liquid biopsy test, licensed from Liquid Biosciences Inc. in March, achieved 100% sensitivity and 95% specificity in a feasibility study. The results suggest the test could detect cancer—and even precancerous lesions—earlier than current methods.
AstraZeneca IncUK-based AstraZeneca plc has become the second of 17 pharmaceutical companies, after Pfizer Inc., to accept U.S. President Donald Trump’s proposal to voluntarily lower drug prices and move production to the United States. In return, the company will benefit from a three-year exemption from U.S. import tariffs on prescription drugs manufactured outside the country.
Asebio - Miguel MéndezAt BioSpain 2025 European Biotechnology spoke with AseBio CEO Ion Arocena about Spain’s expansion in biotech and its role in a time of geopolitical tensions.
Download the guide to explore how forward-thinking organisations are leveraging digital transformation in manufacturing to overcome regulatory challenges, enhance compliance, and gain operational efficiencies across multiple European sites and jurisdictions.
Novo NordiskNovo Nordisk is to acquire US-based Akero Therapeutics in a US$5.2 billion deal aimed at reviving growth and entering the MASH-space where others like Roche and GSK have recently expanded their footprint.
WLan HoldingFairJourney Biologics (Porto, PT) has appointed Dr Werner Lanthaler, long-standing Evotec CEO, as Chief Executive Officer. Founder António Parada will focus on innovation strategy on the Supervisory Board.